A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Human Laboratory, Phase 2 Study of ANS-6637 (GS-6637) for the Treatment of Alcohol Use Disorder
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2018
At a glance
- Drugs ANS 6637 (Primary)
- Indications Alcoholism
- Focus Proof of concept; Therapeutic Use
- 12 Sep 2018 According to an Amygdala Neurosciences media release, the National Institute on Alcohol Abuse and Alcoholism (NIAAA, a division of NIH) will fund and conduct this study at the at leading academic sites.
- 18 Feb 2017 New trial record
- 16 Feb 2017 According to a Amygdala Neurosciences media release, the company plans to initiates this study in 2017.